Brief: ABVC BioPharma and its Subsidiary Receive $460 Mln From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
03/01/2024 12:35
Jan 3 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA AND ITS SUBSIDIARY RECEIVE $460M FROM AIBTL
BIOPHARMA AS THE FIRST MILESTONE PAYMENT OF GLOBAL LICENSING
FEES
Source text for Eikon: ID:nGNX24n26J
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma Says Biokey Share Distribution Rescheduled For August 21
NASDAQ RESUMED AT 09:05 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:43 PM
Brief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon